The Joint Committee on Vaccination and Immunisations (JCVI) has recommended that the HPV immunisation programme should be extended to cover boys.
The JCVI has been reviewing the evidence for vaccinating boys since 2013. Last year it said that extending the programme to cover boys would not be cost effective in an interim statement, however it postponed its final recommendation after agreeing it needed to see further analyses on costs.
In its statement, the JCVI said that under standard economic methodology, extending the vaccine to boys would not be considered cost-effective. However, given that the benefits of the programme would be seen over an extended period of time, it agreed to apply a different rate to assessing the vaccine which meant that a gender neutral programme was deemed to be cost-effective.